Does America have less gas than we think.? Souki said no. He said our country may still have 40,000 wells, the same as last year, but each of those wells is producing more and more gas thanks to better technology. Much of our natural gas supply simply gets burned off, or flared, as a byproduct of oil production, said Souki. "There's plenty of gas for everyone."
Responding to critics who say U.S. gas is best used domestically, Souki said those critics should put their money where their mouths are and build some domestic factories. The gas is here, he said, and they're welcome to use it.
Cramer said Cheniere continues to deliver on its promises and he's still behind the company.
A Breakup in the Making?
The market likes breakup stories and it likes takeovers, Cramer told viewers. Fortunately, there's one company that gives you both possibilities, and that's Agilent (A - Get Report), the measurement and testing company that was spun off from Hewlett-Packard (HPQ) in 1999.Cramer said Agilent has been doing OK so far this year, up 10%, but it's also lagging the markets, making it ripe for a change. He explained the company's life sciences and chemical division has been held back by its cyclical electronics and testing division. While Agilent has made attempts to diversify itself through acquisitions, in the end all it's done is make things harder for investors to quantify. As a breakup play, Cramer said Agilent's parts are certainly worth more than the whole, and the parts can only be fully valued once separated. But what about a takeover? Cramer said Danaher (DHR) is a logical acquirer for Agilent because the company is already in many of Agilent's businesses and there would be a ton of synergies. Danaher has already been on a buying spree and company management has indicated they'd love more life science exposure. Cramer said he never recommends a company on takeover speculation alone, which is why he loves that Agilent was able to post a 10-cents-a-share earnings beat and continues to clean up its operations. In the end, Cramer said Agilent's parts are worth $14.3 billion and $8.3 billion, for a total of $22.6 billion, or $65 a share.
Lightning RoundIn the Lightning Round, Cramer was bullish on Barnes & Noble (BKS), Under Armour (UA), Cisco Systems (CSCO), Pfizer (PFE) and GlaxoSmithKline (GSK). Cramer was bearish on Eagle Rock Energy Partners (EROC), West Corp (WSTC) and Kinder Morgan Energy Partners (KMP).
Executive Decision: JJ BienaimeIn his second "Executive Decision" segment, Cramer spoke with JJ Bienaime, CEO of BioMarin (BMRN - Get Report), a stock that fell 4.6% in today's trading despite compelling new evidence surrounding its breast cancer drugs under development. Bienaime said today's decline in stock price was caused by expectations getting too high for his company's pipeline. He said it was a classic "sell the news" reaction that has nothing to do with BioMarin's test results. When asked about those results, Bienaime said his company's drugs for breast and ovarian cancer are performing well, as they indicated, and there will be even more data presented in September and December of this year. He noted that unlike some other treatments under development, BioMarin's treatment is only one capsule a day, compared to up to 18 capsules a day for others. Bienaime also said the opportunities for drugs under development could be even great with additional indications. When asked what makes BioMarin different than other biotechs and Big Pharma working in the cancer space, Bienaime said BioMarin has always focused on smaller, orphan drugs and that today, cancer treatment is moving away from "one size fits all" treatments and into more specialized drugs that effectively treat only certain indications and mutations of cancers, which is exactly where BioMarin excels. Cramer said BioMarin remains his favorite biotech stock in the group.
No Huddle OffenseIn his "No Huddle Offense" segment, Cramer said it's time to start selling some of the oil stocks because crude prices are on the verge of a major move to the downside. Cramer explained that for weeks now commodities like steel, copper and aluminum have all been falling, signaling a slowdown in the world's emerging markets. Yet, Brent crude prices have held fast above $100, as if to mock the moves in the other commodities. With U.S. oil imports continuing to decline as domestic production increases, Cramer said Brent crude is due a sizable pullback. That may be good news for the U.S. economy, he concluded, but will be bad news for any oil stocks in your portfolio. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts